Literature DB >> 16079166

Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis.

M M J Nielen1, D van Schaardenburg, H W Reesink, J W R Twisk, R J van de Stadt, I E van der Horst-Bruinsma, M H M T de Koning, M R Habibuw, B A C Dijkmans.   

Abstract

OBJECTIVE: To investigate the temporal relationship between onset of inflammation (as measured by secretory phospholipase A2 (sPLA2) and C reactive protein (CRP)) and the presence of autoantibodies (IgM rheumatoid factor (IgM RF) and antibodies against citrullinated peptides (anti-CCP)) in the preclinical phase of rheumatoid arthritis (RA).
METHODS: For 79 patients with RA who had been blood donors before the onset of disease, a median of 13 serum samples per patient was available. sPLA2 was measured in patient and matched control samples and related to previous CRP, IgM RF, and anti-CCP measurements. The temporal relationship between the increased markers of inflammation and autoantibodies was analysed with time lag analysis.
RESULTS: IgM RF and anti-CCP concentrations were significantly associated (p<0.001) with concentrations of sPLA2, CRP, and the combination of sPLA2 and CRP at the same time point. However, we found no stronger association between the two autoantibody tests and the three inflammation measures 1, 2, and 3 years before or after a time point than for measurements at the same time, in the whole group or in subgroups of IgM RF and anti-CCP positive patients.
CONCLUSION: Both the acute phase response and autoantibody formation often develop years before the first symptoms of RA occur, and these phenomena are probably closely connected in time.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16079166      PMCID: PMC1798080          DOI: 10.1136/ard.2005.040659

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  6 in total

1.  Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis.

Authors:  Markus M J Nielen; Dirkjan van Schaardenburg; Henk W Reesink; Jos W R Twisk; Rob J van de Stadt; Irene E van der Horst-Bruinsma; Truus de Gast; Moud R Habibuw; Jan P Vandenbroucke; Ben A C Dijkmans
Journal:  Arthritis Rheum       Date:  2004-08

2.  Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.

Authors:  Solbritt Rantapää-Dahlqvist; Ben A W de Jong; Ewa Berglin; Göran Hallmans; Göran Wadell; Hans Stenlund; Ulf Sundin; Walther J van Venrooij
Journal:  Arthritis Rheum       Date:  2003-10

3.  Rheumatoid factors antedating clinical rheumatoid arthritis.

Authors:  K Aho; M Heliövaara; J Maatela; T Tuomi; T Palosuo
Journal:  J Rheumatol       Date:  1991-09       Impact factor: 4.666

4.  Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors.

Authors:  Markus M J Nielen; Dirkjan van Schaardenburg; Henk W Reesink; Rob J van de Stadt; Irene E van der Horst-Bruinsma; Margret H M T de Koning; Moud R Habibuw; Jan P Vandenbroucke; Ben A C Dijkmans
Journal:  Arthritis Rheum       Date:  2004-02

5.  Therapy with interleukin-2 induces the systemic release of phospholipase-A2.

Authors:  G J Wolbink; C Schalkwijk; J W Baars; J Wagstaff; H van den Bosch; C E Hack
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

6.  Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.

Authors:  Geraldine Cambridge; Maria J Leandro; Jonathan C W Edwards; Michael R Ehrenstein; Martin Salden; Mark Bodman-Smith; Anthony D B Webster
Journal:  Arthritis Rheum       Date:  2003-08
  6 in total
  53 in total

1.  Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) Family Study: rationale and design for a randomized controlled trial evaluating rheumatoid arthritis risk education to first-degree relatives.

Authors:  Jeffrey A Sparks; Maura D Iversen; Rachel Miller Kroouze; Taysir G Mahmoud; Nellie A Triedman; Sarah S Kalia; Michael L Atkinson; Bing Lu; Kevin D Deane; Karen H Costenbader; Robert C Green; Elizabeth W Karlson
Journal:  Contemp Clin Trials       Date:  2014-08-20       Impact factor: 2.226

Review 2.  Environmental and gene-environment interactions and risk of rheumatoid arthritis.

Authors:  Elizabeth W Karlson; Kevin Deane
Journal:  Rheum Dis Clin North Am       Date:  2012-05-30       Impact factor: 2.670

3.  The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner.

Authors:  Kevin D Deane; Colin I O'Donnell; Wolfgang Hueber; Darcy S Majka; Ann A Lazar; Lezlie A Derber; William R Gilliland; Jess D Edison; Jill M Norris; William H Robinson; V Michael Holers
Journal:  Arthritis Rheum       Date:  2010-11

4.  Anti-arthritic activity of ferulic acid in complete Freund's adjuvant (CFA)-induced arthritis in rats: JAK2 inhibition.

Authors:  Lijuan Zhu; Zhenshan Zhang; Nannan Xia; Weifeng Zhang; Yanlin Wei; Jiashu Huang; Zhijuan Ren; Feilong Meng; Lei Yang
Journal:  Inflammopharmacology       Date:  2019-09-27       Impact factor: 4.473

5.  Lifetime exposure to self-reported occupational noise and prevalent rheumatoid arthritis in the National Health and Nutrition Examination Survey (2011-2012).

Authors:  Angel M Dzhambov; Donka D Dimitrova
Journal:  Int J Occup Environ Health       Date:  2018-03-20

6.  A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA.

Authors:  Jason R Kolfenbach; Kevin D Deane; Lezlie A Derber; Colin O'Donnell; Michael H Weisman; Jane H Buckner; Vivian H Gersuk; Shan Wei; Ted R Mikuls; James O'Dell; Peter K Gregersen; Richard M Keating; Jill M Norris; V Michael Holers
Journal:  Arthritis Rheum       Date:  2009-12-15

Review 7.  Strategies to predict rheumatoid arthritis development in at-risk populations.

Authors:  Elizabeth W Karlson; Dirkjan van Schaardenburg; Annette H van der Helm-van Mil
Journal:  Rheumatology (Oxford)       Date:  2014-08-04       Impact factor: 7.580

8.  Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints.

Authors:  Adrienn Angyal; Colt Egelston; Tamás Kobezda; Katalin Olasz; Anna László; Tibor T Glant; Katalin Mikecz
Journal:  Arthritis Res Ther       Date:  2010-03-18       Impact factor: 5.156

9.  Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis.

Authors:  Linda L Hushaw; Ray Sawaqed; Ghaleb Sweis; Jori Reigle; Anjali Gopal; Daniel Brandt; Nadia Sweis; James Curran; Timothy B Niewold; Nadera J Sweiss
Journal:  Ther Clin Risk Manag       Date:  2010-04-15       Impact factor: 2.423

Review 10.  Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.

Authors:  Jean-Michel Dayer; Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2009-10-23       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.